Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CD160 is an 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Additionally we are shipping CD160 Proteins (14) and CD160 Kits (7) and many more products for this protein.
Showing 10 out of 173 products:
Mouse (Murine) Monoclonal CD160 Primary Antibody for FACS - ABIN2659122
Cai, Freeman: The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. in Immunological reviews 2009
Show all 4 references for ABIN2659122
Human Monoclonal CD160 Primary Antibody for ICFC - ABIN2662470
Barakonyi, Rabot, Marie-Cardine, Aguerre-Girr, Polgar, Schiavon, Bensussan, Le Bouteiller: Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. in Journal of immunology (Baltimore, Md. : 1950) 2004
Show all 4 references for ABIN2662470
Mouse (Murine) Monoclonal CD160 Primary Antibody for FACS - ABIN2659984
Shui, Steinberg, Kronenberg: Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. in Journal of leukocyte biology 2011
Show all 4 references for ABIN2659984
Mouse (Murine) Monoclonal CD160 Primary Antibody for ELISA (Capture), ELISPOT (Capture) - ABIN2662468
del Rio, Lucas, Buhler, Rayat, Rodriguez-Barbosa: HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. in Journal of leukocyte biology 2010
Show all 4 references for ABIN2662468
Mouse (Murine) Monoclonal CD160 Primary Antibody for FACS - ABIN2656960
Tsujimura, Obata, Matsudaira, Nishida, Akatsuka, Ito, Demachi-Okamura, Kuzushima, Takahashi: Characterization of murine CD160+ CD8+ T lymphocytes. in Immunology letters 2006
Show all 4 references for ABIN2656960
Human Polyclonal CD160 Primary Antibody for EIA, WB - ABIN951200
Schmitt, Ghazi, Bellier, Bensussan: Identification and analysis of the human CD160 promoter: implication of a potential AML-1 binding site in promoter activation. in Genes and immunity 2009
Show all 2 references for ABIN951200
CD160 functionally controls cytokine production by natural killer cells.
Report additive effects of IL-22 (show IL22 Antibodies) and CD160 in mediating the pro-inflammatory and pro-survival aspects of the host mucosal response in Clostridium difficile infection.
During chronic infection the number of CD4 (show CD4 Antibodies)(+) T cells expressing programmed death-1 (show PDCD1 Antibodies) and CD160 were greater over the time-course study than the other CD4 (show CD4 Antibodies)(+) T-cell inhibitory ligands.
CD160 signaling is particularly important in CD28 (show CD28 Antibodies)-independent effector/memory CD8 (show CD8A Antibodies)(+) alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection.
soluble CD160, produced by mast cells, may have a role in T-cell-mast cell interactions in vivo
CD160 is expressed on the majority of CD8 (show CD8A Antibodies)(+) memory T cells as well as recently activated CD8 (show CD8A Antibodies)(+) T cells
CD160 and CD200 (show CD200 Antibodies) are expressed in B cells in chronic lymphocytic leukemia and are absent in other mature B-cell neoplasms.
Data suggest that CD160 may become a useful marker in the clinical diagnosis and prognosis of chronic lymphocytic leukemia.
elevated CD160 expression on natural killer (NK) cells plays an important role in NK cell loss in atherosclerosis.
CD160-expressing human NK cells are costimulated by HVEM (show TNFRSF14 Antibodies) expressed in the environment to enhance cytolytic function and cytokine production.
analysis of how NK1 receptor Gs versus Gq proteins and beta-arrestin signaling is determined by interactions in the water hydrogen bond network
identified 13 ADCC-activated genes. Six gene expression assays including 8 of the 13 genes (CCL3 (show CCL3 Antibodies), CCL4/CCL4L1 (show CCL4 Antibodies)/CCL4L2, CD160, IFNG (show IFNG Antibodies), NR4A3 (show NR4A3 Antibodies) and XCL1 (show XCL1 Antibodies)/XCL2 (show XCL2 Antibodies)) were analyzed in 127 kidney biopsies
report high frequencies of CD160 on CD8 (show CD8A Antibodies)+ T cells, with significantly higher levels on HTLV-1 specific CD8 (show CD8A Antibodies)+ T cells
A population of CD4 (show CD4 Antibodies)+ CD160+ T lymphocytes was identified in circulating cutaneous T cells.
Antibodies targeting CD160-GPI (show GNPDA1 Antibodies) complement the blockade of PD-1 (show PDCD1 Antibodies) to enhance HIV-specific T-cell responses and warrant further investigation in the development of novel immunotherapeutic approaches.
CD160 and PD-1 (show PDCD1 Antibodies) co-expression on HIV-specific CD8 (show CD8A Antibodies) T cells defines a subset with advanced dysfunction.
CD160 is an 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich, glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules.
, CD160 antigen
, natural killer cell BY55
, natural killer cell receptor BY55
, CD160 transmembrane isoform
, CD160-delta Ig
, natural killer cell receptor, immunoglobulin superfamily member